Smart Vitamins

smartvitamins.org ↗ ·Santiago de Compostela ·Seed

Smart Vitamins is a University of Santiago de Compostela (CiMUS) biotech spin-off that develops SDN Technology (Smart Delivery of Nutrients), a nanovehicle platform created in María José Alonso's nanomedicine lab that delivers essential nutrients selectively to target tissues for pharmaceutical, nutraceutical and cosmeceutical applications. Its lead asset, SV B-I, is an intranasal spray for influenza prevention that showed 100% protection in rodent preclinical studies; in March 2025 the company raised €2.1M to fund its first human clinical trial, planned to start in the UK in early 2026. It is headquartered in Santiago de Compostela (Galicia), and no venture capital fund appears in its cap table — its backers are pharma/health business angels (Vicente Durán of Medpoint, Antonio Parente of GP Pharm/BCN Peptides, Roberto Conde of Cantabria Labs, Santiago Domínguez of Sémola Ventures, Mauricio Peralta, José Luis del Río of Arcano, Roberto Pomares of Addleshaw Goddard España).

Founded

2020

Founders

Total funds raised

€2.1M

SectorsBiotech, Nanomedicine, Drug Delivery, Nutraceuticals, Healthtech Start-up MapHealthtech & Bio › R&D tools & software for life sciences

Suggest a correction

Founders

Alfredo Bermúdez de Castro

Co-founder, Chairman & CEO

María Dolores Torres

Co-founder & Technical Director

María José Alonso

Co-founder & Scientific Director

Also at Libera Bio →

Rubén Varela

Co-founder

Global models 3

Leyden Labs

Netherlands · www.leydenlabs.com ↗

VC-backed biotech developing intranasal sprays to prevent influenza and other respiratory viruses, the same use case as Smart Vitamins' lead asset SV B-I.

$210MComparable

Ena Respiratory

Australia · www.enarespiratory.com ↗

Clinical-stage biotech developing a nasal spray that primes innate immunity to prevent influenza and other respiratory infections, taken from preclinical work into human trials.

$25MComparable

Pneumagen

United Kingdom · www.pneumagen.com ↗

University spin-out developing an intranasal, strain-independent spray to prevent influenza and other respiratory viruses, funded by venture rounds through early clinical trials.

$16MComparable